Key clinical point: A triple-combination inhaler reduced COPD exacerbations, compared with a dual-drug inhaler.
Major finding: The rate of moderate/severe exacerbations was 1.08 and 1.07 for the combinations with budesonide vs. 1.42 for a LAMA/LABA and 1.24 for an ICS/LABA combo.
Study details: Randomized trial in 85,09 patients with COPD.
Disclosures: The ETHOS trial was funded by AstraZeneca. Dr. Rabe disclosed consulting/advisory board activity with the company and others. Dr. Han has previously disclosed consulting/advising and research funding relationships with other companies.
Rabe KF et al. N Engl J Med. 2020 Jun 24. doi: 10.1056/NEJMoa1916046.